Docosahexaenoic acid - Beth Israel Deaconess Medical Center/Cystic Fibrosis Foundation/Genzyme
Alternative Names: DHA - Beth Israel Deaconess Medical Center/Cystic Fibrosis Foundation/Genzyme; LumarelLatest Information Update: 13 Jan 2022
At a glance
- Originator Beth Israel Deaconess Medical Center
- Class Antihyperlipidaemics; Docosahexaenoic acids; Eye disorder therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cystic fibrosis
Most Recent Events
- 08 Mar 2001 Discontinued-Preclinical for Cystic fibrosis in USA (Unknown route)
- 05 Nov 1999 Preclinical development for Cystic fibrosis in USA (Unknown route)